Therapeutic apheresis in neurological disorders: A survey of the evidence in support of current category I and II indications for therapeutic plasma exchange

Journal of Clinical Apheresis

Volumn 23, Issue 6, 2008, Pages 196-201

  Weinstein, Robert ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Guillain Barr syndrome; Neurology; Plasma exchange; Therapeutic apheresis

Indexed keywords

ANTICONVULSIVE AGENT; AZATHIOPRINE; CHOLINESTERASE INHIBITOR; CORTICOSTEROID DERIVATIVE; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; PLACEBO; PREDNISONE; PYRIDOSTIGMINE;

ACUTE INFLAMMATORY DEMYELINATING POLYNEUROPATHY; APHERESIS; ARTICLE; CHOREA MINOR; CLINICAL STUDY; CLINICAL TRIAL; DEMYELINATING DISEASE; DRUG MEGADOSE; EATON LAMBERT SYNDROME; GUILLAIN BARRE SYNDROME; HEALTH SURVEY; HUMAN; IMMUNOGLOBULIN A DEFICIENCY; IMMUNOGLOBULIN G DEFICIENCY; IMMUNOGLOBULIN M DEFICIENCY; MYASTHENIA GRAVIS; NEUROLOGIC DISEASE; PARAPROTEINEMIA; PEDIATRIC AUTOIMMUNE NEUROPSYCHIATRIC DISORDERS ASSOCIATED WITH STREPTOCOCCAL INFECTIONS; POLYNEUROPATHY; POLYRADICULONEUROPATHY; PSYCHOSIS; RANDOMIZATION; RASMUSSEN SYNDROME; TREATMENT INDICATION; TREATMENT OUTCOME; PLASMAPHERESIS; PRACTICE GUIDELINE; REVIEW;

BLOOD COMPONENT REMOVAL; HUMANS; NERVOUS SYSTEM DISEASES; PLASMA EXCHANGE; PRACTICE GUIDELINES AS TOPIC;

EID: 59449108312     PISSN: 07332459     EISSN: 10981101     Source Type: Journal    
DOI: 10.1002/jca.20178     Document Type: Article

References (62)

1. Clark WF, Rock GA, Buskard N, Shumak KH, LeBlond P, Anderson D, Sutton DM. Therapeutic plasma exchange: an update from the Canadian Apheresis Group. Ann Intern Med 1999; 131:453-462.
2. Szczepiorkowski ZM, Bandarenko N, Kim HC, Linenberger ML, Marques MB, Sarode R, Schwartz J, Shaz BH, Weinstein R, Wirk A, Winters JL. Guidelines on the use of therapeutic apheresis in clinical practice-Evidence-based approach from the apheresis applications committee of the American society for apheresis. J Clin Apheresis 2007;22:106-175.
3. Szczepiorkowski ZM, Shaz BH, Bandarenko N, Winters JL, The new approach to assignment of ASFA categories - introduction to the fourth special issue: clinical applications of therapeutic apheresis. J Clin Apheresis 2007;22:96-105.
4. Ropper AH. The Guillain-Barré syndrome. N Engl J Med 1992; 326:1130-1136.
5. Koski CL, Humphrey R, Shin ML. Anti-peripheral myelin antibody in patients with demyelinating neuropathy: quantitative and kinetic determination of serum antibody by complement component 1 fixation. Proc Natl Acad Sci USA 1985;82:905-909.
6. Weinstein R. Is there a scientific rationale for therapeutic plasma exchange or intravenous immune globulin in the treatment of acute Guillain-Barré syndrome? J Clin Apheresis 1995;110:150-157.
7. Brettle RP, Gross M, Legg NJ, Lockwood M, Pallis C. Treatment of acute polyneuropathy by plasma exchange. Lancet 1978; 2:1100.
8. Valbonesi M, Garelli S, Mosconi L, Zerbi D, Celano I. Plasma, exchange as a therapy for Guillain-Barré syndrome with immune complexes. Vox Sang 1981;41:74-78.
9. Zerbi D, Celano I, Forlani G, Garelli S, Mosconi L, Valbonesi M. Plasmapheresis in the treatment of four cases of GuillainBarré syndrome (acute form). Ital J Nourol Sci 1981;2:331-336.
10. de Jager AE, The TH, Smit Sibinga CT, Das PC. Plasma exchange in five patients with acute Guillain Barré syndrome. Int J Artif Organs 1981;4:230-233.
11. Rumpl E, Mayr U, Gerstenbrand F, Hackl JM, Rosmanith P, Aichner F. Treatment of Guillain-Barré syndrome by plasma exchange. J Neurol 1981;225:207-217.
12. Kennard C, Newland AC, Ridley A. Treatment of the GuillainBarré syndrome by plasma exchange. J Neurol Neurosurg Psychiatry 1982;45:847-850.
13. Bezwoda WR, Eritz V, Reef HE, Staub H, Derman DP, Lewis M, KallenFach J, Zaltzman M, Naughton MA. Treatment of acute post-infective polyneuropathy by means of plasma exchange. Acta Neurol Scand 1984;69:112-119.
14. Greenwood RJ, Newsom-Davis J, Hughes RA, Aslan S, Bowden AN, Chadwick DW, Gordon NS, McLellan DL, Millac P. Stott RB, Armitage P. Controlled trial of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet 1984;1:877-879.
15. Osterman PO, Fagius J, Lundemo G, Pihlstedt P, Pirskanen R, Sidén A, Säfwenberg J. Beneficial effects of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet 1984;2: 1296-1299.
16. The Guillain-Barré syndrome Study Group. Plasmapheresis and acute Guillain-Barré syndrome. Neurology 1985;35:1096-1104.
17. French Cooperative Group on Plasma Exchange in GuillainBarré Syndrome. Efficiency of plasma exchange in GuillainBarré syndrome: role of replacement fluids. Ann Neurol 1987; 22:753-761.
18. French Cooperative Group on Plasma Exchange in GuillainBarré Syndrome. Plasma exchange in Guillain-Barré syndrome: one-year follow-up. Ann Neurol 1992;32:94-97.
19. Gorson KC, Allam G, Ropper AH. Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology 1997;48:321-328.
20. Levy RL, Newkirk R, Ochoa J. Treating chronic relapsing Guillain- Barré syndrome by plasma exchange. Lancet 1979;2:259-260.
21. Server AC, Lefkowith J, Braine H, McKhann GM. Treatment of chronic relapsing inflammatory polyradiculoneuropathy by plasma exchange. Ann Neurol 1979;6:258-261.
22. Gross ML, Thomas PK. The treatment of chronia relapsing and chronic progressive idiopathic inflammatory polyneuropathy by plasma exchange. J Neurol Sci 1981;52:69-78.
23. van Nunen SA, Gatenby PA, Pollard JD, Deacon M, Clancy RL. Specificity of plasmapheresis in the treatment of chronic relapsing polyneuropathy. Aust N Z J Med 1982;12:81-84.
24. Gross ML, Legg NJ, Lockwood MC, Pallis C. The treatment of inflammatory polyneuropathy, by plasma exchange. J Neurol Neurosurg Psychiatry 1982;45:675-679.
25. Toyka KV, Augspach R, Wiethölter H, Besinger UA, Haneveld F, Liebert UG, Heininger K, Schwendemann G, Reiners K, Grabensee B. Plasma exchange in chronic inflammatory polyneuropathy: evidence suggestive of a pathogenic humoral factor. Muscle Nerve 1982;5:479-484.
26. Pollard JD, McLeod JG, Gatenby P, Kronenberg H. Prediction of response to plasma exchange in chronic relapsing polyneuropathy. A clinico-pathological correlatioh. J Neurol Sci 1983; 58:269-287.
27. Dyck PJ, Daube J, O'Brien P, Pineda A, Low PA, Windebank AJ, Swanson C. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy; N Engl J Med 1986;314 461-465.
28. Hahn AF, Bolton CF, Pillay N, Chalk C, Bensteal T, Bril V, Shumak K, Vandervoort MK, Feasby TE. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study. Brain 1996; 119:1055-1066.
29. Dyck PJ, Litchy WJ, Kratz KM, Suarez GA, Low PA, Pineda AA, Windebank AJ, Karnes JL, O'Brien PC. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 1994;36:838-845.
30. Batocchi AP, Evoli A, Di Schino C, Tonali P. Therapeutic apheresis in myasthenia gravis. Ther Apher 2000;4:275-279.
31. Weinstein R. Therapeutic apheresis in neurological disorders. J Clin Apheresis 2000;15:74-128.
32. Qureshi AI, Suri MFK. Plasma exchange for treatment of myasthenia gravis: pathophysiologic basis and clinical experience. Ther Apher 2000;4:280-286.
33. Gajdos P, Simon N, de Rohan-Chabot P, Raphael JC, Goulon M. Long-term effects of plasma exchange in myasthenia. Results of a randomized study. Presse Med 1983;12:939-942.
34. Gajdos P, Chevret S, Toyka K. Plasma exchange for myasthenia gravis. Cochrane Database Syst Rev 2002, Issue 4. Art. No.:CD002275; DOI: 10.1002/14651858.CD002275.
35. Rønager J, Ravnborg M, Hermansen I, Vorstrup S. Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to severe myasthenia gravis. Artif Organs 2001;25:967-973.
36. Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia grayis clinical study group. Ann Neurol 1997;41:789-796.
37. Technology Assessment Subcommittee of the American Academy of Neurology. Assessment of plasmapheresis. Report of the therapeutics and technology assessment subcommittee of the american academy of neurology. Neurology 1996;47:840-843.
38. Lehmann HC, Hartung HP, Hetzel GR, Stüve, O, Kieseier BC. Plasma exchange in neuroimmunological disorders: part 2. Treatment of neuromuscular disorders. Arch Neurol 2006;63:1066-1071.
39. Ropper AH, Gorson KC. Neuropathies associated with paraproteinemia. N Engl J Med 1998;338:1601-1607.
40. Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of paraproteinemic demyelinating neuropathies. Report of a joint task force of the European federation of neurological societies and the peripheral nerve society. J Peripher Nerv Syst 2006;11:9-19.
41. Dyck PJ, Low PA, Windebank AJ, Jaradeh SS, Gosselin S, Bourque P, Smith BE, Kratz KM, Karnes JL, Evans BA, Pineda AA, O'Brien PC, Kyle RA. Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance. N Engl J Med 1991;325:1482-1486.
42. Kenneth CG, Allan HR. Axonal neuropathy associated with monoclonal gammopathy of undetermined significance. J Neurol Neurosurg Psychiatry 1997;63:163-168.
43. Nobile-Orazio E, Meucci N, Baldini L, Di Troia A, Scarlato G. Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies. Brain 2000;123:710-717.
44. Oksenhendler E, Chevret S, Léger JM, Louboutin JP, Bussel A, Brouet JC. Plasma exchange and chlorambucil in polyneuropathy associated with monoclonal IgM gammopathy. IgM-associated polyneuropathy study group. J Neurol Neurosurg Psychiatry 1995;59:243-247.
45. Lunn MP, Nobile-Orazio E. Immunotherapy for IgM anti-myelin- associated glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database Syst Rev 2006, Issue 2. Art. No.: CD002827; DOI: 10.1002/ 14651858.CD002827.pub2.
46. Seneviratne U, de Silva R. Lambett-Eaton myasthenic syndrome. Postgrad Med J 1999;75:516-520.
47. Motomura M, Hamasaki S, Nakane S, Fukuda T, Nakao YK. Apheresis treatment in Lambert-Eaton myasthenic syndrome. Ther Apher 2000;4:287-290.
48. Garvey MA, Snider LA, Leitman SF, Werden R, Swedo SE. Treatment of Sydenham's chorea with intravenous immunoglobulin, plasma cxchange, or prednisone. J Child Neurol 2005;20:424-429.
49. Perlmutter SJ, Leitman SF, Garvey MA, Hamburger S, Feldman E, Leonard HL, Swedo SE. Therapeutic plasma exchange and intravenous immunoglobulin for obsessive-compulsive disorder and tic disorders in childhood. Lancet 1999;354:1153-1158.
50. Rasmussen T, Olszewski J, Lloyd-Smith D. Focal seizures due to chronic localized encephalitis. Neurology 1958;8:435-445.
51. Rasmussen T. Hemispherectomy for seizures revisited. Can J Neurol Sci 1983;10:71-78.
52. Vining EP, Freeman JM, Pillas DJ, Uematsu S, Carson BS, Brandt J, Boatman D, Pulsifer MB, Zuckerberg A. Why would you remove half a brain? The outcome of 58 children after hemispherectomy-the Johns Hopkins experience: 1968 to 1996. Pediatrics 1997;100:163-171.
53. Rogers SW, Andrews PI, Gahring LC, Whisenand T, Cauley K, Crain B, Hughes TE, Heinemann SF, McNamara JO. Autoantibodies to glutamate receptor GluR3 in Rasmussen's encephalitis. Science 1994;265:648-651.
54. Mantegazza R, Bernasconi P, Baggi F, Spreafico R, Ragona F, Antozzi C, Bernardi G, Granata T. Antibodies against GluR3 peptides are not specific for Rasmussen's encephalitis but are also present in epilepsy patients with severe, early onset disease and intractable seizures. J Neuroimmunol 2002;131:179-185.
55. Watson R, Jiang Y, Bermudez I, Houlihan L, Clover L, McKnight K, Cross JH, Hart IK, Roubertie A, Valmier J, Hart Y, Palace J, Beeson D, Vincent A, Lang B. Absence of antibodies to glutamate receptor type 3 (GluR3) in Rasmussen encephalitis. Neurology 2004;63:43-50.
56. Goodin DS, Frohman EM, Garmany GP Jr., Halper J, Likosky WH, Lublin FD, Silberberg DH, Stuart WH, van den Noort S. Disease modifying therapies in multiple sclerosis: subcommittee of the American Academy of neurology and the MS council for clinical practice guidelines. Neurology 2002;58:169-178.
57. Available at http://www.neurology.org/cgi/data/58/2/169/DC3/1. Accessed on 26 September 2008.
58. Lehmann HC, Hartung HP, Hetzel GR, Stüve O, Kieseier BC. Plasma exchange in neuroimmunological disorders: part 1. Rationale and treatment of inflammatory central nervous system disorders. Arch Neurol 2006;63:930-935.
59. Dau PC, Petajan JH, Johnson KP, Panitch HS, Bornstein MB. Plasmapheresis in multiple sclerosis: preliminary findings. Neurology 1980;30:1023-1028.
60. Valbonesi M, Garelli S, Mosconi L, Zerbi D, Forlani G. Plasma exchange in the management of patients with multiple sclerosis: preliminary observations. Vox Sang 1981;41:68-73.
61. Rodriguez M, Karnes WE, Bartleson JD, Pineda AA. Plasmapheresis in acute episodes of fulminant CNS inflammatory demyelination. Neurology 1993;43:1100-1104.
62. Weinshenker BG, O'Brien PC, Petterson TM, Noseworthy JH, Lucchinetti CF, Dodick DW, Pineda AA, Stevens LN, Rodriguez M. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999;46:878-886.